<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33947793</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1943-3654</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>66</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Respiratory care</Title>
          <ISOAbbreviation>Respir Care</ISOAbbreviation>
        </Journal>
        <ArticleTitle>In Vitro Comparison of Different Nebulizers Delivering 7% Hypertonic Saline.</ArticleTitle>
        <Pagination>
          <StartPage>1582</StartPage>
          <EndPage>1587</EndPage>
          <MedlinePgn>1582-1587</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.4187/respcare.08834</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Nebulized 7% hypertonic saline is used to treat patients with cystic fibrosis. Clinical trials supporting its use were conducted with breath-enhanced nebulizers (BEN). It is not uncommon for the specific nebulizer used in studies or prescribed by a physician to be unavailable to patients. The investigator compared the aerosol characteristics of hypertonic saline delivered by nebulizers of different operating principles.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">A continuous-output nebulizer (CON), a breath-actuated (BAN) jet nebulizer, and 2 brands of BEN (Pari LC Plus and Sidestream Plus) were tested. Airway delivery and aerosol characteristics of nebulizers loaded with 7% hypertonic saline were determined with 3 breathing simulations (ie, infant, child, and adult breathing patterns) and cascade impaction, respectively. Solutes were analyzed with freezing point osmometry.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Aerosols generated with the BEN and BAN had similar mass median aerodynamic diameters (3.43-3.67 <b>µ</b>m), geometric standard deviations (2.12-2.34), percentage of particles &lt; 5 <b>µ</b>m (63.1-68.9%), and percentage of particles 1-3 <b>µ</b>m (35.9-37%). The CON produced a larger aerosol than BEN and BAN. The 2 BENs had similar airway delivery values that were greater than those for both CON and BAN.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Hypertonic saline aerosols generated with the BEN and BAN devices were similar, while that generated with the CON was different. Airway delivery was similar between the BEN devices, but higher than that observed with the BAN and CON devices.</AbstractText>
          <CopyrightInformation>Copyright © 2021 by Daedalus Enterprises.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Berlinski</LastName>
            <ForeName>Ariel</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, University of Arkansas for Medical Sciences, College of Medicine, Little Rock, Arkansas. berlinskiariel@uams.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Pediatric Aerosol Research Laboratory, Arkansas Children's Research Institute, Little Rock, Arkansas.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Respir Care</MedlineTA>
        <NlmUniqueID>7510357</NlmUniqueID>
        <ISSNLinking>0020-1324</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000336">Aerosols</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>QF8SVZ843E</RegistryNumber>
          <NameOfSubstance UI="D000420">Albuterol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000336" MajorTopicYN="N">Aerosols</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000420" MajorTopicYN="Y">Albuterol</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009330" MajorTopicYN="Y">Nebulizers and Vaporizers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">aerosol characteristics</Keyword>
        <Keyword MajorTopicYN="N">breath-actuated jet nebulizer</Keyword>
        <Keyword MajorTopicYN="N">breath-enhanced jet nebulizer</Keyword>
        <Keyword MajorTopicYN="N">continuous output jet nebulizer</Keyword>
        <Keyword MajorTopicYN="N">cystic fibrosis</Keyword>
        <Keyword MajorTopicYN="N">hypertonic saline</Keyword>
      </KeywordList>
      <CoiStatement>Dr Berlinski has disclosed relationships with AbbVie, Allergan, Anthera, DCI, Cempra, Cystic Fibrosis Foundation, Mylan, National Institute of Health, Therapeutic Development Network, Trudell Medical International, Vertex, Vivus, and the International Pharmaceutical Aerosol Consortium on Regulation and Science.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>5</Day>
          <Hour>5</Hour>
          <Minute>54</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33947793</ArticleId>
        <ArticleId IdType="doi">10.4187/respcare.08834</ArticleId>
        <ArticleId IdType="pii">respcare.08834</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
